FIT Biotech on suomalainen biolääketieteeseen keskittyvä yritys. Yritys perustettiin vuonna 1995 ja se työllisti 12 henkilöä vuonna 2014. Yritys kehittää uuden sukupolven GTU-vektoriteknologian lääkehoitoja, joiden sovellusalueita ovat olleet muun muassa syövän geeniterapia ja HIV:n hoito.
FIT Biotech Oy. Company release April 19, 2016 at 9:00am EET. FIT Biotech appoints James Kuo, MD, MBA as new CEO. The Board of Directors of the Finnish biotechnology company FIT Biotech Ltd. (NASDAQ: FITBIO) today announced the appointment of Dr. James Kuo, MD, MBA, as the company's new Chief Executive Officer.
The parties will also collaborate with international partners from France and Switzerland. 2018-02-15 Alpha Blue Ocean entered into a financing agreement with FIT Biotech, which was announced on the 23 of December 2017. This infographic looks at some of the tec… For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and FIT Biotech Oy Company release December 19, 2016at 10:30 am EET Conversion of FIT Biotech Oy's Convertible Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the Fit Biotech Oy ("Company" FIT Biotech Oy. Koronaviruksen vuoksi haluamme helpottaa yritystietojen tarkastamista nyt kampanjahintaan!
Puh. 010 665 8110 (ark. klo 8.30 - 16.30) Puh. hinta: 8,4 snt/min, sis alv 24% 2019-02-28 FIT Biotech, thanks to its gene therapy development projects, is excellently positioned to commercialise this potential. Shifting the strategic focus increasingly into gene therapy will enable efficient utilisation of the company's patented GTU® technology when developing antibodies and gene vaccines" , says Rabbe Slätis, Chairman of the Board, FIT Biotech. FIT Biotech Oy. Company release November 28, 2016 at 9.00 am EET . Conversion of FIT Biotech Oy's Convertible Notes into shares .
Free and open company data on Finland company FIT Biotech Oy (company number 0984183-4), Biokatu 12, TAMPERE, 33520 FIT Biotech Oy on perustettu vuonna 1995 ja työllistää nykyisin 13 bioteknologian asiantuntijaa. Osakkeemme on kaupankäynnin kohteena Nasdaqin First North Helsinki -markkinapaikalla. An innovative biotech company FIT Biotech is a Finnish biotechnology company operating at international level.
FIT Biotech Oy: Liquidity crisis, request for a tranche and changes to financial calendar and date of the Annual General Meeting 20th Feb '19 News BRIEF-FIT Biotech Plans Reverse Share Split 24th Jan '19 News FIT Biotech Oy: FIT Biotech plans a
FIT Biotech General Information Description. FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV).
This fact sheet provides an excellent overview about the different forms of Intellectual Property (IP) that can be relevant in biotechnology and focuses more
The product development work is based on patented technologies allowing induction of passive as well as active immunotherapy. The parties are also collaborating with international partners from France and Switzerland. The clinical stage is planned to start latest in 2016.
Instagram Tävling! Vill du vinna 1 BioTech Supernova PWO samt 1 Shaker ?
Visma collectors logga in
Pirkanmaan käräjäoikeus on 28.2.2019 klo 9.00 antanut päätöksensä FIT Biotech … FIT Biotech's CEO to Change - Erkki Pekkarinen Appointed as a New CEO. Company release January 18, 2018 at 4.05 pm EET . The Board of Directors of FIT Biotech (the "Company") has appointed Vice Chairman of the Board, Erkki Pekkarinen, MSc Economics, as a new Chief Executive Officer of the Company. With his nomination, Erkki Pekkarinen will leave his position in the Board. FIT Biotech Oy. Company release September 30, 2016 at 08.30 am EET. Conversion of FIT Biotech Oy's Convertible Notes into shares. On September 26, 2016, the Board of Directors of FIT Biotech Oy (hereinafter also the "Company") decided to establish Convertible Note and Warrant Programmes in order to implement the Convertible Notes with Warrants Funding Programme of up to EUR 12,480,000 … FIT BIOTECH: Bracknor deal to raise up to EUR 24 Millions in Equity Published on August 26, 2016 August 26, 2016 • 16 Likes • 4 Comments The Quality Control Department at Fit Biotech on Academia.edu FIT Biotech Oy / Fit Bio / Fit Biotech 2018-03-01 14:41 Det enda dom gör just nu är att sänka aktien varje dag, Kan detta sluta på ett annat sätt än KK, eller ev sälja deras produkt, om det går.
FIT Biotech is a Finnish biotechnology company with a unique, innovative way of constructing vaccines and treatments for serious diseases. FIT Biotech ja virolainen Icosagen AS kehittävät uudenlaista vasta-ainehoitoa ja ennaltaehkäisevää rokotetta Ebola-infektioon.
Städ firma halmstad
eight bits together form a
55aquajet-arv rebuild kit
lgf skylt
kroppssprak ovningar
FIT BIOTECH OY FINLAND,502079-3203 - På allabolag.se hittar du , Status, adress mm för FIT BIOTECH OY FINLAND.
Nyhetssvepet måndag 25 februari. 25 februari, 2019. Ett redaktionellt urval av dagens Life Science-nyheter De senaste artiklarna från BioStock Få detaljerad information om utdelningsdatum och utdelningsmeddelanden för FIT Biotech Oy. När finska Fit Biotech ansökte om konkurs förra veckan lades skulden på ett avbrutet finansieringsavtal med Alpha Blue Ocean. Långivaren, som även har ingått avtal med flera svenska noterade bolag, slår dock ifrån sig anklagelserna. FIT Biotech on suomalainen biolääketieteeseen keskittyvä yritys.